Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Shashidhara Haragadde Poppareddy"'
Autor:
Mithua Ghosh, Radheshyam Naik, Sheela Mysore Lingaraju, Sridhar Papaiah Susheela, Shekar Patil, Gopinath Kodaganur Srinivasachar, Satheesh Chiradoni Thungappa, Krithika Murugan, Srinivas Belagutty Jayappa, Somorat Bhattacharjee, Nalini Rao, Mahesh Bandimegal, Roopesh Krishnappa, Shashidhara Haragadde Poppareddy, Krishna Chennagiri Raghavendrachar, Yogesh Shivakumar, Sunitha Nagesh, Ramya Kodandapani, Ashwini Rajan, Urvashi Bahadur, Pooja Agrawal, Veena Ramaswamy, Tejaswini Bangalore Nanjaiah, Sateesh Kunigal, Shanmukh Katragadda, Ashwini Manjunath, Amritanshu Ram, Basavalinga S. Ajaikumar
Publikováno v:
Translational Oncology, Vol 14, Iss 1, Pp 100877- (2021)
Breast cancer (BC) is a heterogeneous disease. Numerous chemotherapeutic agents are available for early stage or advanced/metastatic breast cancer to provide maximum benefit with minimum side effects. However, the clinical outcome of patients with th
Externí odkaz:
https://doaj.org/article/e9673ac8e9e6409397fe2c7fd81d504b
Autor:
Shashidhara Haragadde Poppareddy, Vibhor Sharma, Vanita Noronha, Vijay Patil, Ashish Kaushal, Chandragouda Dodagoudar, Jyoti Bajpai, Govind Babu, Rohan Tewani, Nandini Menon, T Raja, Navneet Singh, Kumar Prabhash, Ramya Ananthakrishnan, Sudeep Gupta, Amit Joshi, Amit Agarwal, Ullas Batra, Shekhar Patil, George M. Abraham, Vivek S. Radhakrishnan, Naresh Somani, Saphalta Baghmar, Ashish Joshi, Senthil Rajappa
Publikováno v:
International journal of cancerREFERENCES. 150(6)
The real-world data on short-course of ICI use is sparse and merits exploration. A multi-centric observational study on the safety and efficacy of ICI in oncology patients between August 2014 to October 2020 involving 1011 patients across 13 centers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aeffba5d09ae3761aff6eacd12f43158
https://pubmed.ncbi.nlm.nih.gov/34751432
https://pubmed.ncbi.nlm.nih.gov/34751432
Autor:
Satheesh Chiradoni Thungappa, Krishna Chennagiri Raghavendrachar, Gopinath Kodaganur Srinivasachar, Nalini Rao, Sridhar Papaiah Susheela, Sheela Mysore Lingaraju, Shekar Patil, Mithua Ghosh, Srinivas Belagutty Jayappa, Sunitha Nagesh, Urvashi Bahadur, Veena Ramaswamy, Somorat Bhattacharjee, Ashwini Manjunath, Shanmukh Katragadda, Sateesh S. Kunigal, Roopesh Krishnappa, Mahesh Bandimegal, Basavalinga S. Ajaikumar, Amritanshu Ram, Shashidhara Haragadde Poppareddy, Radheshyam Naik, K. Murugan, Yogesh Shivakumar, Ashwini Rajan, Tejaswini Bangalore Nanjaiah, Pooja Agrawal, Ramya Kodandapani
Publikováno v:
Translational Oncology
Translational Oncology, Vol 14, Iss 1, Pp 100877-(2021)
Translational Oncology, Vol 14, Iss 1, Pp 100877-(2021)
Breast cancer (BC) is a heterogeneous disease. Numerous chemotherapeutic agents are available for early stage or advanced/metastatic breast cancer to provide maximum benefit with minimum side effects. However, the clinical outcome of patients with th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7f2c6a614ab63155589645de7718ae9
https://doi.org/10.1016/j.tranon.2020.100877
https://doi.org/10.1016/j.tranon.2020.100877